Compare MPB & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | DRTS |
|---|---|---|
| Founded | 1868 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 978.2M |
| IPO Year | 1996 | N/A |
| Metric | MPB | DRTS |
|---|---|---|
| Price | $33.49 | $9.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $37.00 | $8.67 |
| AVG Volume (30 Days) | 116.0K | ★ 965.6K |
| Earning Date | 04-21-2026 | 05-18-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | $699.98 |
| P/E Ratio | $91.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.50 | $2.87 |
| 52 Week High | $35.22 | $11.62 |
| Indicator | MPB | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 50.50 |
| Support Level | $30.82 | $6.59 |
| Resistance Level | $34.88 | $11.48 |
| Average True Range (ATR) | 0.83 | 0.83 |
| MACD | 0.07 | -0.10 |
| Stochastic Oscillator | 66.50 | 32.17 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.